Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook
· seekingalpha.com
Plus Therapeutics (CNSY) Q2 press release: GAAP EPS -$1.31 missed by $0.45; cash & investments $8.6M as of June 30, 2026.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...